Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate pessaries for cervical precancer
NCT06165614Phase 1Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in cervical intraepithelial neoplasia (CIN), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Type, frequency, severity and duration of adverse events at 14 weeks. Started Mar 2024; status: completed.
02
Drugs
artesunate
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT06165614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165614.